PL2529033T3 - Sposoby do przewidywania ryzyka, diagnozowania i prognozowania zaburzeń płucnych - Google Patents
Sposoby do przewidywania ryzyka, diagnozowania i prognozowania zaburzeń płucnychInfo
- Publication number
- PL2529033T3 PL2529033T3 PL11737602T PL11737602T PL2529033T3 PL 2529033 T3 PL2529033 T3 PL 2529033T3 PL 11737602 T PL11737602 T PL 11737602T PL 11737602 T PL11737602 T PL 11737602T PL 2529033 T3 PL2529033 T3 PL 2529033T3
- Authority
- PL
- Poland
- Prior art keywords
- prognosis
- diagnosis
- methods
- risk prediction
- pulmonary disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4725—Mucins, e.g. human intestinal mucin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29847310P | 2010-01-26 | 2010-01-26 | |
| US29881410P | 2010-01-27 | 2010-01-27 | |
| US32323810P | 2010-04-12 | 2010-04-12 | |
| US32376010P | 2010-04-13 | 2010-04-13 | |
| EP11737602.0A EP2529033B1 (en) | 2010-01-26 | 2011-01-26 | Methods for risk prediction, diagnosis, prognosis of pulmonary disorders |
| PCT/US2011/022621 WO2011094345A1 (en) | 2010-01-26 | 2011-01-26 | Methods and compositions for risk prediction, diagnosis, prognosis, and treatment of pulmonary disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2529033T3 true PL2529033T3 (pl) | 2017-10-31 |
Family
ID=44319751
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11737602T PL2529033T3 (pl) | 2010-01-26 | 2011-01-26 | Sposoby do przewidywania ryzyka, diagnozowania i prognozowania zaburzeń płucnych |
Country Status (10)
| Country | Link |
|---|---|
| US (6) | US8673565B2 (pl) |
| EP (1) | EP2529033B1 (pl) |
| CA (2) | CA3101636A1 (pl) |
| DK (1) | DK2529033T3 (pl) |
| ES (1) | ES2636671T3 (pl) |
| HU (1) | HUE033044T2 (pl) |
| MX (1) | MX344543B (pl) |
| PL (1) | PL2529033T3 (pl) |
| SI (1) | SI2529033T1 (pl) |
| WO (1) | WO2011094345A1 (pl) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3101636A1 (en) | 2010-01-26 | 2011-08-04 | National Jewish Health | Diagnosis and prognosis of idiopathic interstitial pneumonia by rs35705950 snp in muc5b gene promoter |
| US20140315210A1 (en) * | 2011-12-21 | 2014-10-23 | University College Dublin, National University Of Ireland, Dublin | Methods relating to idiopathic pulmonary fibrosis (ipf) |
| WO2014121180A1 (en) * | 2013-02-01 | 2014-08-07 | The University Of Chicago | Genetic variants in interstitial lung disease subjects |
| KR102544414B1 (ko) * | 2013-02-14 | 2023-06-15 | 더 리전츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트 | 간질 폐렴의 위험을 예측하는 방법 |
| EP3626308A1 (en) | 2013-03-14 | 2020-03-25 | Veracyte, Inc. | Methods for evaluating copd status |
| EP4219761A1 (en) * | 2013-03-15 | 2023-08-02 | Veracyte, Inc. | Biomarkers for diagnosis of lung diseases and methods of use thereof |
| JP6141160B2 (ja) | 2013-09-25 | 2017-06-07 | ソニーセミコンダクタソリューションズ株式会社 | 固体撮像素子およびその動作方法、並びに電子機器およびその動作方法 |
| CN107206043A (zh) | 2014-11-05 | 2017-09-26 | 维拉赛特股份有限公司 | 使用机器学习和高维转录数据在经支气管活检上诊断特发性肺纤维化的系统和方法 |
| EP3285794B1 (en) * | 2015-04-22 | 2020-03-18 | The University of Chicago | Methods for treating idiopathic pulmonary fibrosis |
| NZ760756A (en) | 2017-06-26 | 2024-02-23 | Univ Colorado Regents | Biomarkers for the diagnosis and treatment of fibrotic lung disease |
| WO2021142245A1 (en) * | 2020-01-10 | 2021-07-15 | Translate Bio, Inc. | Compounds, pharmaceutical compositions and methods for modulating expression of muc5b in lung cells and tissues |
| WO2022087329A1 (en) * | 2020-10-23 | 2022-04-28 | Alnylam Pharmaceuticals, Inc. | Mucin 5b (muc5b) irna compositions and methods of use thereof |
| WO2023105527A1 (en) * | 2021-12-09 | 2023-06-15 | Splisense Ltd. | Muc5-targeted antisense oligonucleotides and related methods for modulating expression of muc5ac and muc5b |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| EP0247091B1 (en) | 1985-11-01 | 1993-09-29 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5637459A (en) | 1990-06-11 | 1997-06-10 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: chimeric selex |
| US5496938A (en) | 1990-06-11 | 1996-03-05 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands to HIV-RT and HIV-1 rev |
| US5582981A (en) | 1991-08-14 | 1996-12-10 | Gilead Sciences, Inc. | Method for identifying an oligonucleotide aptamer specific for a target |
| US5777085A (en) | 1991-12-20 | 1998-07-07 | Protein Design Labs, Inc. | Humanized antibodies reactive with GPIIB/IIIA |
| US6210671B1 (en) | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
| US5830645A (en) | 1994-12-09 | 1998-11-03 | The Regents Of The University Of California | Comparative fluorescence hybridization to nucleic acid arrays |
| US7144699B2 (en) * | 1997-03-20 | 2006-12-05 | Affymetrix, Inc. | Iterative resequencing |
| US6339075B1 (en) | 1997-06-30 | 2002-01-15 | The University Of British Columbia | Use of dextran and other polysaccharides to improve mucus clearance |
| TW589189B (en) | 1997-08-04 | 2004-06-01 | Scras | Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
| GB9827152D0 (en) | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
| KR100483494B1 (ko) | 1998-12-01 | 2005-04-15 | 프로테인 디자인 랩스 인코포레이티드 | 감마 인터페론에 대한 인간화 항체 |
| CA2361201A1 (en) | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| EP1235842A4 (en) | 1999-10-15 | 2003-04-23 | Univ Massachusetts | GENESIS OF THE RNA INTERFERENCE PATH AS AID OF TARGETED GENTIAN INTERFERENCE |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| US20020037538A1 (en) * | 2000-05-09 | 2002-03-28 | Trepicchio William L. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of psoriasis |
| JP2004532616A (ja) | 2000-12-28 | 2004-10-28 | ジョンソン・アンド・ジョンソン・リサーチ・ピー・ティー・ワイ・リミテッド | 二本鎖ｒｎａ仲介遺伝子抑制 |
| US20030092019A1 (en) * | 2001-01-09 | 2003-05-15 | Millennium Pharmaceuticals, Inc. | Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia |
| US20030040009A1 (en) | 2001-08-14 | 2003-02-27 | University Of Southern California | Saliva-based methods for preventing and assessing the risk of diseases |
| US6818446B2 (en) * | 2001-11-21 | 2004-11-16 | The Regents Of The University Of California | Compositions and methods for the analysis of mucin gene expression and identification of drugs having the ability to inhibit mucin gene expression |
| AU2002950878A0 (en) | 2002-08-20 | 2002-09-12 | Proteome Systems Intellectual Property Pty Ltd | Method for diagnosing disorders |
| EP1403638A1 (en) | 2002-09-25 | 2004-03-31 | Mondobiotech SA | Molecular methods for diagnosing interstitial lung diseases |
| US7300788B2 (en) * | 2002-10-08 | 2007-11-27 | Affymetrix, Inc. | Method for genotyping polymorphisms in humans |
| US20070202109A1 (en) * | 2003-09-24 | 2007-08-30 | Oncotherapy Science, Inc. | Method Of Diagnosing Breast Cancer |
| US20050125851A1 (en) * | 2003-12-09 | 2005-06-09 | Children's Hospital Research Foundation | Methods of diagnosis and treatment of interstitial lung disease |
| JP4825956B2 (ja) | 2004-05-19 | 2011-11-30 | 財団法人ヒューマンサイエンス振興財団 | 気道粘膜炎症性疾患の罹患リスクの判定 |
| KR20080011292A (ko) | 2005-05-19 | 2008-02-01 | 시너젠즈 바이오사이언스 리미티드 | 유전자 다형 분석을 사용하여 폐암 발생 위험을 평가하는방법 |
| CA2666584A1 (en) | 2006-10-17 | 2008-04-24 | Synergenz Bioscience Limited | Methods and compositions for assessment of pulmonary function and disorders |
| US20100119474A1 (en) | 2007-03-06 | 2010-05-13 | Cornell University | Chronic obstructive pulmonary disease susceptibility and related compositions and methods |
| US20120094842A1 (en) * | 2007-11-01 | 2012-04-19 | Peter Durie | Methods of assessing and treating pulmonary disease |
| WO2009073167A2 (en) | 2007-12-03 | 2009-06-11 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Identification and diagnosis of pulmonary fibrosis using mucin genes, and related methods and compositions |
| WO2009140715A1 (en) | 2008-05-21 | 2009-11-26 | Central Northern Adelaide Health Service | Diagnostic method |
| DE102010027032A1 (de) | 2009-07-20 | 2011-02-17 | Sigismund Laskowski | Trageverpackung zur Aufnahme von Behältnissen |
| CA3101636A1 (en) | 2010-01-26 | 2011-08-04 | National Jewish Health | Diagnosis and prognosis of idiopathic interstitial pneumonia by rs35705950 snp in muc5b gene promoter |
-
2011
- 2011-01-26 CA CA3101636A patent/CA3101636A1/en active Pending
- 2011-01-26 HU HUE11737602A patent/HUE033044T2/hu unknown
- 2011-01-26 WO PCT/US2011/022621 patent/WO2011094345A1/en active Application Filing
- 2011-01-26 CA CA2787994A patent/CA2787994C/en active Active
- 2011-01-26 DK DK11737602.0T patent/DK2529033T3/en active
- 2011-01-26 SI SI201131250T patent/SI2529033T1/sl unknown
- 2011-01-26 PL PL11737602T patent/PL2529033T3/pl unknown
- 2011-01-26 US US13/014,589 patent/US8673565B2/en active Active
- 2011-01-26 MX MX2012008730A patent/MX344543B/es active IP Right Grant
- 2011-01-26 ES ES11737602.0T patent/ES2636671T3/es active Active
- 2011-01-26 EP EP11737602.0A patent/EP2529033B1/en active Active
-
2014
- 2014-02-03 US US14/171,536 patent/US20140220570A1/en not_active Abandoned
-
2016
- 2016-07-22 US US15/217,885 patent/US20170183730A1/en not_active Abandoned
-
2017
- 2017-11-02 US US15/802,281 patent/US10858707B2/en active Active
-
2020
- 2020-11-06 US US17/091,507 patent/US11649503B2/en active Active
-
2023
- 2023-04-25 US US18/306,648 patent/US20230313307A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011094345A1 (en) | 2011-08-04 |
| US11649503B2 (en) | 2023-05-16 |
| CA3101636A1 (en) | 2011-08-04 |
| CA2787994A1 (en) | 2011-08-04 |
| EP2529033B1 (en) | 2017-05-24 |
| EP2529033A1 (en) | 2012-12-05 |
| US20110217315A1 (en) | 2011-09-08 |
| MX344543B (es) | 2016-12-19 |
| US20140220570A1 (en) | 2014-08-07 |
| US20210198738A1 (en) | 2021-07-01 |
| US8673565B2 (en) | 2014-03-18 |
| US20170183730A1 (en) | 2017-06-29 |
| US20230313307A1 (en) | 2023-10-05 |
| US10858707B2 (en) | 2020-12-08 |
| MX2012008730A (es) | 2012-12-17 |
| SI2529033T1 (sl) | 2017-08-31 |
| DK2529033T3 (en) | 2017-08-07 |
| US20190040467A1 (en) | 2019-02-07 |
| CA2787994C (en) | 2021-01-12 |
| ES2636671T3 (es) | 2017-10-06 |
| HUE033044T2 (hu) | 2017-11-28 |
| EP2529033A4 (en) | 2013-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2529033T1 (sl) | Postopki za napovedovanje tveganja, diagnozo, prognozo pljučnih obolenj | |
| HK1200933A1 (zh) | 改善炎性腸病診斷的方法 | |
| IL222232A0 (en) | Circulating biomarkers for disease | |
| EP2606353A4 (en) | CIRCULATING BIOMARKERS FOR DISEASE | |
| PL2748605T3 (pl) | Sposoby i kompozycje do diagnozowania i prognozowania uszkodzenia nerek i niewydolności nerek | |
| EP2788759A4 (en) | METHODS AND COMPOSITIONS FOR DIAGNOSING AND PROGNOSING KIDNEY INJURY AND RENAL FAILURE | |
| EP2556479A4 (en) | METHOD FOR MONETIZING ANONYMIZED CONTEXTS | |
| RS55406B1 (sr) | Novi ko-kristali agomelatina | |
| EP2723866A4 (en) | METHOD FOR THE PROGNOSIS AND / OR DIAGNOSIS OF NEURODEEGENERATIVE DISEASES, METHOD FOR IDENTIFYING COMPOUND CANDIDATES AND COMPOUNDS FOR THE TREATMENT OF NEURODEGENATIVE DISEASES | |
| EP2888370A4 (en) | DIAGNOSIS, FORECASTING AND TREATMENT PROCEDURES | |
| EP2696756A4 (en) | METHODS FOR THE DIAGNOSIS, PROGNOSIS, MONITORING AND TREATMENT OF HEPATOCELULAR CARCINOMA | |
| IL231982A0 (en) | A method for the diagnosis of Niemann-Pick disease | |
| EP2729803A4 (en) | METHODS AND COMPOSITIONS FOR DIAGNOSING AND PROGNOSING RENAL INJURY AND RENAL FAILURE | |
| EP2661626A4 (en) | METHOD AND COMPOSITIONS FOR DIAGNOSIS AND FORECASTING kidney injury and kidney insufficiency | |
| EP2783213A4 (en) | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE | |
| GB201011420D0 (en) | Method for diagnosis | |
| EP2539714A4 (en) | BIOMARKERS OF MUSCULOSKELETAL DISEASE | |
| HK1200877A1 (en) | Method for monitoring, diagnosis and/or prognosis of hypoxia related disorders using nfat5 nfat5 / | |
| EP2704800A4 (en) | PROCESS FOR PREDICTING THE DEVELOPMENT OF COMPLEMENT-MEDIATED DISEASES | |
| EP2598875A4 (en) | PROCESS FOR SCOLIOSIS DIAGNOSIS ON BIOMEDICAL BASIS | |
| EP2653872A4 (en) | BIOMARKERS FOR AMYLOID-BETA-MEDIATED NEUROLOGICAL ILLNESSES | |
| AP2013006853A0 (en) | Biomarker for vavular heart disease | |
| IL228581A0 (en) | Compounds and methods for treatment, diagnosis and detection of disease | |
| ZA201401630B (en) | Method for assessing perspiration reduction | |
| GB201001073D0 (en) | Methods & Devices for diagnosing cardiac disorders |